A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).
about
Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label.Recombinant activated factor VII in controlling bleeding in non-hemophiliac patientsRecombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective.Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors.Inhibitors in congenital coagulation disorders.Therapy for haemophilia: recent advances and goals for the future.The promise and challenges of bioengineered recombinant clotting factors.Identifying and managing inhibitor patients requiring orthopaedic surgery - the multidisciplinary team approach.The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review.Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patientsHaemophilia therapies.Inhibitor development in haemophilia B: an orphan disease in need of attention.Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors.Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.Home treatment of haemophilia patients with inhibitors.Proteases as therapeutics.Pharmacotherapy of haemophilia A.The hope and reality of long-acting hemophilia products.Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomesRapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients.Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitorsRecombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial.Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients.A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.Recombinant activated factor VII.Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist.Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).Pharmacokinetics and safety of a 270 mcg kg-1 dose of room temperature stable recombinant activated factor VII in patients with haemophilia.A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.Evaluation of algorithms for the treatment of problem bleeding episodes in patients with hemophilia having inhibitors.PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
P2860
Q31102998-508FEC51-0277-4DDA-BD76-D59FE584C8CEQ33918017-A254B9D2-2E56-46A6-BE80-46AACB475ACEQ35167279-F90BF24F-8A29-448E-8E63-CB26FE7F863BQ35691941-71819968-B89F-4DAD-A41A-BE43FAAB362BQ35771690-728D6E19-E1FD-4502-8DAA-5093BAB598E6Q35937076-733F7807-3BB2-44D6-86AF-D9DAB7035E2BQ36066048-023F3E52-BA01-4561-90AE-33297F76AFC5Q36230850-2287AF36-B421-4B71-8747-D8D5044725ADQ36283838-C6F70859-B6CC-4B25-8D34-BBDCA81A34D2Q36480548-F972245E-C768-4F36-9F92-0E78715924BEQ36536184-EDDE22D2-1C11-43EB-8C8D-C62491483777Q36570888-8F815879-38EF-42E8-A171-5D0B28E513A4Q36745575-E74204EF-9675-4BCD-ADE2-BDB6BA07E7D9Q36810282-245F49F5-BBC5-48C3-B613-76FE52361779Q36872038-8071BFE6-326E-453A-AA5E-7373CF04590CQ36985329-19384BF8-EB55-48BF-9FB4-97AFFF0672A1Q37169669-ABFC195F-DF43-4D87-89A5-A20C61C83CA3Q37609087-5D67D60E-5D1C-4B67-BC06-6D02173B2C49Q37778292-04A536A4-90EE-4C4A-B9FB-ED6D9BABFF6EQ37808746-882094A9-3949-4328-8B58-54B87CB96772Q37853216-FDA594F2-AC56-48E4-8E48-C3C67965204CQ37891089-36853CCD-7318-4D94-88CA-4D3D85A3928DQ37990479-3B85DFFE-7052-4B4F-91E6-3D163D002894Q38235951-74CCAD7E-537C-4A3E-A2E9-F69D463B9F85Q38546790-CB85406D-3DCE-43B1-9CFD-E4DDD888B6CAQ40539842-954E9663-8C2D-46AC-A1BB-1D6A43BAAAFAQ43893957-D385A4C6-6F64-4852-8F60-B00C89209A7CQ44514782-B13C06E7-747E-4FF2-8355-6922145E278AQ45855313-77C371B3-E633-4212-A059-7BB8FEA915BEQ45859185-6938FDC0-88F5-457E-81A4-E08B41D2AC99Q45861831-17A5BD59-D898-4D6F-B369-4C1CCF733FC4Q45864880-D2A795A7-2A7A-4004-BDBB-E8505DDFAA59Q45865116-6CBCBF50-6277-4E35-8A56-74F0B5B787A1Q45866922-6B20C9B8-08D9-4461-9E6A-E843253D1CCCQ45867946-DABC392E-3D6A-44C3-B662-0A5438F56222Q45868043-86912F2D-F423-4574-BF2E-3DB25B6B3EE8Q45869629-2E162604-2486-4320-B749-AEA0E58CF7C9Q45870435-8CE9101E-90E4-461E-96BB-9D0D42921EFAQ45872851-36692AE2-F807-456A-BA33-C27592674162Q45873703-1938A2FE-51CA-4367-A4C9-14B3FD4F2369
P2860
A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
A new approach to treatment of ...... ivated factor VII (NovoSeven).
@en
A new approach to treatment of ...... combinant activated factor VII
@nl
type
label
A new approach to treatment of ...... ivated factor VII (NovoSeven).
@en
A new approach to treatment of ...... combinant activated factor VII
@nl
prefLabel
A new approach to treatment of ...... ivated factor VII (NovoSeven).
@en
A new approach to treatment of ...... combinant activated factor VII
@nl
P2093
P2860
P1476
A new approach to treatment of ...... ivated factor VII (NovoSeven).
@en
P2093
A Lubetsky
J Luboshitz
U Martinowitz
P2860
P304
P356
10.1046/J.1538-7836.2003.00059.X
P577
2003-03-01T00:00:00Z